Abstract: The present invention pertains to the use of conjugated zearalenone (ZEA) in a method to protect an animal against ZEA induced mycotoxicosis, in particular to protect against decreased weight gain, kidney damage, liver damage and damage to a reproductive organ.

Abstract: The present invention pertains to the use of conjugated T-2 toxin (T2) in a method to protect an animal against T2 induced mycotoxicosis, in particular to protect against a decrease in average daily weight gain, intestinal damage, skin damage and snout damage, thus one or more of these signs of mycotoxicosis induced by T2 as a result of the ingestion of T2.

Abstract: For the prevention of parasite infestation of animals, an isoxazoline can be administered by drinking water route. However the inventors have found that when the drinking water is sanitized, for instance by using hypochlorite, the isoxazoline becomes degraded. Surprisingly, the isoxazoline can be protected from degradation by the use of a vitamin E. A pharmaceutical composition can now be prepared containing a concentrated solution of the isoxazoline in a solvent and co-solvent, with vitamin E. The composition can be diluted in drinking water, even when sanitized, to prepare medicated drinking water for animals. This way an anti-parasitic treatment can be mass-administered, leading to a highly effective reduction of the parasite infestation of an animal, and its surroundings.

Abstract: The present invention pertains to a vaccine comprising in combination non-replicating immunogen of porcine circo virus type 2 (PCV2), non-replicating immunogen of Mycoplasma hyopneumoniae and conjugated deoxynivalenol (DON) for protecting swine against an infection with porcine circo virus type 2, an infection with Mycoplasma hyopneumoniae and DON induced mycotoxicosis.

Abstract: The present invention provides recombinant vectors encoding a chimeric coronavirus spike protein. The present invention further provides new immunogenic compositions and vaccines comprising these recombinant vectors. Methods of administering these immunogenic compositions and vaccines to animal subjects, including humans, felines, and avians, to protect them against coronaviruses also are included. Methods of making the immunogenic compositions and vaccines alone or in combinations with other protective agents are provided too.

Abstract: The present invention provides caninized rat antibodies to canine IL-31 receptor alpha that have a high binding affinity for canine EL-31 receptor alpha, and that can block the binding of canine IL-31 to canine EL-31 receptor alpha. The present invention further provides the use of the antibodies for the treatment of atopic dermatitis in dogs.

Abstract: The subject invention is the novel use of an injectable pharmaceutical composition comprising tildipirosin for the treatment and prophylaxis of foot rot. The use of a single subcutaneous dose of tildipirosin has been demonstrated to effectively treat naturally occurring foot rot.

Abstract: The application relates to a process to produce large isoxazoline compound particles which comprises initiating crystallization and then maintaining the temperature of the crystallization in the metastable region by removing, reheating and recycling a portion of the solvent thereby allowing the existing crystals to grow larger while minimizing the formation of newer smaller crystals.

Abstract: A method for external fish parasite monitoring in aquaculture, comprising the steps of: submerging a camera (52) in a sea pen containing fish, the camera having a field of view; capturing images of the fish with the camera (52); and identifying external fish parasite on the fish by analyzing the captured images, characterized in that a target region within the field of view of the camera (52) is illuminated from above and below with light of different intensities and/or spectral compositions.

Abstract: The invention relates to a live attenuated parvovirus for use in the protection of an animal against parvovirus infection, wherein the live attenuated parvovirus is administered to the animal as a single dose and is administered during weeks 2-10 of age of the animal. The invention further relates to vaccines comprising the live attenuated parvovirus as well as methods for their production.

Abstract: The invention concerns a baculovirus expression vector for recombinantly expressing an FMDV capsid precursor protein under control of a promoter, the expression vector comprising a nucleic acid sequence encoding the FMDV capsid precursor protein and the translational enhancers Syn2 land p10UTR. The invention further relates to a host cell comprising the baculovirus expression vector, a method of producing FMDV virus-like particles (VLPs), and a method of producing a vaccine.

Abstract: The present invention provides caninized rat antibodies to canine IL-31 receptor alpha that have a high binding affinity for canine IL-31 receptor alpha, and that can block the binding of canine IL-31 to canine IL-31 receptor alpha. The present invention further provides the use of the antibodies for the treatment of atopic dermatitis in dogs.

Abstract: A buccal administration method of flunixin has been developed now to provide an easy to use and effective method of reducing pain in livestock animals (e.g. swine, cattle, sheep, goats, etc.).

Abstract: The invention concerns a baculovirus expression vector for recombinantly expressing a Foot-and-mouth disease virus (FMDV) capsid precursor protein under control of a promoter, the expression vector comprising a nucleic acid sequence encoding the FMDV capsid precursor protein, wherein the ATG start codon of an open reading frame encoding the FMDV capsid precursor protein © is preceded at position ?4 to ?1 by the nucleic acid sequence 5?-AAAT-3?. The invention further relates to a host cell comprising the baculovirus expression vector, a method of producing FMDV virus-like particles (VLPs), and a method of producing a vaccine.

Abstract: The present invention pertains to a vaccine comprising an immunologically effective amount of an IgM protease antigen of Streptococcus suis, for use in a method for protecting pigs against a pathogenic infection with Streptococcus suis by administering the vaccine only once, wherein the vaccine comprises at most 120 ?g per dose of the antigen.

Abstract: A system for external fish parasites monitoring in aquaculture, the system comprising: —a camera (52) suitable to be submerged in a sea pen suitable for containing comprising fish, the camera being arranged for capturing images of the fish; and—an electronic image processing system (86) configured for identifying external fish parasites on the fish by analyzing the captured images, wherein: —a ranging detector (54) configured for detecting the presence of fish and measuring a distance from the detector to the fish is mounted adjacent to the camera (52); and—an electronic control system (12) is arranged to control a focus of the camera (52) on the basis of the measured distance and to trigger the camera (52) when a fish has been detected within a predetermined distance range.

Abstract: The present invention pertains to a method for automatic sea lice monitoring in fish aquaculture, the method comprising submerging a camera (4) in a sea pen (300) comprising fish, using the camera to make an image of at least one of said fish, analysing the image to differentiate between individual sea lice present on the fish and the fish itself and assessing the number of sea lice present on the fish, wherein the camera is attached to a device (1, 10, 100) for guiding the salmon along an imaging track (5), the camera being directed to the track.

Abstract: The present invention provides new vaccines for felines and ferrets to aid in reducing shedding of severe acute respiratory syndrome coronavirus 2 by infected felines or ferrets. Methods of making and using the vaccines alone or in combinations with other protective agents are also provided.

Abstract: The present invention relates to a novel equine parvovirus associated with respiratory distress and recurrent laryngeal neuropathy in equine, to nucleic acid fragments and proteins of the virus and to vaccines based upon the virus, proteins and nucleic acid fragments. The invention also relates to a diagnostic test for the detection of the vims or antibodies against the virus.

Abstract: The invention pertains to a combination of a first vaccine comprising anon-replicating immunogen of porcine circovirus type 2 (PCV-2) and a non-replicating immunogen of Mycoplasma hyopneumoniae, and a second vaccine comprising a live attenuated porcine reproductive and respiratory syndrome (PRRS) virus, for use in prophylactically treating a pig against an infection with PCV-2, an infection with Mycoplasma hyopneumoniae and an infection with PRRS virus, by associated separate injection of the first vaccine and the second vaccine into a tissue of the pig at a first and a second injection site respectively, wherein the first and second injection sites are at most 5 cm apart from each other.